CTOs on the Move

Dynarex Corporation

www.dynarex.com

 
Dynarex Corporation is a Orangeburg, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.dynarex.com
  • 10 Glenshaw St
    Orangeburg, NY USA 10962
  • Phone: 888.335.7500

Executives

Name Title Contact Details

Similar Companies

Alfagene Bioscience

Alfagene Bioscience is a Fords, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Honson Industries

Honson Industries Ltd is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mera Pharmaceuticals

Mera Pharmaceuticals is a Kailua Kona, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Our products are helping to address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. We are improving people’s quality of life by preventing, alleviating or curing diseases. We are helping to provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. In line with our mission “Bayer: Science For A Better Life”, we aim to improve people’s quality of life. For this endeavor, we focus on our core competency of developing and successfully commercializing innovative products and solutions based on scientific knowledge.

Savara Pharmaceuticals

Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.